Welcome

Please select your view

comprehensivejpg

Comprehensive Somatic Mutation Testing

Comprehensive Gene Panel of Somatic Mutation Testing in Solid Tumours

Australian Clinical Labs offers a Comprehensive Tumour Somatic Mutation Panel including 26 oncogenes and tumour suppressor genes that are frequently mutated in solid tumours aiding clinicians to select the most appropriate treatment for their patients.

When to use

This panel can be helpful in elucidating the genetic profile of multiple gene pathways of a given tumour which is potentially useful in designing tailored treatment regimens that avoid unnecessary toxic therapy, resistance or overtreatment. It is also of valuable use if the tumour is poorly differentiated or of unknown origin. Larger gene panel profiling may actually identify previously unknown, clinically relevant alterations that are germline, either de novo or inherited from parents, despite a lack of associated clinical history.

Gene panel includes:

AKT1 EGFR GNAQ MET PTEN
ALK ERBB2 GNAS MSH6 SMAD4
APC FBXW7 KIT NRAS SRC
BRAF FGFR2 KRAS PDGFRA STk11
CDH1 FOXL2 MAP2k1 PIK3CA TP53
CTNNB1        
When to Order: Comprehensive Diagnostic Protocol for Solid Tissue Cancers.
How to Order: Fill out our Somatic Mutation testing request form and tick the Somatic Mutation test panels required.
Turnaround Time: 5-7 business days after the receipt of the sample.
Specimen Required: Formalin-fixed paraffin-embedded (FFPE) tissue of a solid cancer tumour.
Test Cost: The Comprehensive Tumour Somatic Mutation Panel (TruSight Tumour) is Non-Medicare rebatable. An out-of-pocket fee of $750 applies.

Download Somatic Mutation Request Form Download Somatic Mutation Request Form (WA)



The content on our Molecular Cancer Services page is written by National Clinical Director of Molecular Genetic Pathology at Australian Clinical Labs, Associate Professor Mirette Saad

 

Assoc. Prof. Mirette Saad

MBBS (Hons), MD, MAACB, FRCPA, PhD
Lab: Clayton
Speciality: Chemical Pathology and Molecular Genetics
Areas Of Interest: Cancer Genetics, Antenatal Screening, NIPT, Endocrine, Fertility Testing and Research, Medical Teaching
Phone: 1300 134 111
Email: mirette.saad@clinicallabs.com.au

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Clinical Director of Molecular Genetic Pathology at Australian Clinical Labs. Associate Professor Saad obtained her fellowship in Chemical and Molecular Pathology with a clinical Microbiology sub-specialty in Egypt.

After several posts, she worked as a Medical Laboratory Director in private labs and as an Associate Professor and Examiner of Clinical Chemistry for postgraduate and undergraduate medical and nursing students at various institutions. Upon receiving the National Health and Medical Research (NHMRC) Scholarship in 2006, Associate Professor Saad commenced her PhD studies at Melbourne University and Peter MacCallum Cancer Institute in Cancer Genetics. Associate Professor Saad undertook her specialty training at Healthscope Pathology (now Australian Clinical Labs) and Monash Health and obtained the Chemical Pathology Fellowship (FRCPA) and the Membership (MAACB) by examination from the Royal College of Pathologists of Australasia (RCPA) and the Australasian Association of Clinical Biochemists (AACB) respectively.

She is currently a member of the Chemical Pathology Advisory Committee at RCPA. At Clinical Labs, A/P Saad supervises the antenatal screening program including combined First Trimester Screening and Non-Invasive Prenatal Testing (NIPT) along with the Molecular Genetic testing for hereditary disorders, personalised drug therapy and cancer.

Back to Molecular Cancer Services Homepage